Cargando…
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors, with limited progress made in the area of myeloid malignancies. The low mutational burden of acute myeloid leukemia (AML) is one potential reason behind the lack of activity of T-cell harnessing ICIs, particu...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318025/ https://www.ncbi.nlm.nih.gov/pubmed/35883692 http://dx.doi.org/10.3390/cells11142249 |